Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Vancomycin-resistant S. aureus was cultured from the exit site of a temporary dialysis catheter of a patient with diabetes, peripheral vascular disease, and persistent foot ulcers. The organism carried the vanA resistance gene, which may have come from the vancomycin-resistant Enterococcus faecalis that was also isolated from the patient, who had received vancomycin for several weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increasing rates of oxacillin-resistant S aureus or MRSA isolates in both hospital and community settings and the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“and is especially prevalent in North America.6,138,139”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Diagnostic molecular microbiology : principles and applications
Persing, D. H. (1993) · ASM Press eBooks · Cited by 1,311
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Self-citation(2001) · PsycEXTRA Dataset · doi:10.1037/e548252006-001 · Cited by 1,018
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Arthur, M., Molinas, C., Depardieu, F., & Courvalin, P. (1993) · Journal of Bacteriology · doi:10.1128/jb.175.1.117-127.1993 · Cited by 603
Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus
Bannerman, T. L., Hancock, G. A., Tenover, F. C., & Miller, J. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.3.551-555.1995 · Cited by 550
Self-citationCharacterization of glycopeptide-resistant enterococci from U.S. hospitals
Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., & Tenover, F. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2311 · Cited by 395
Self-citationApplication of pulsed-field gel electrophoresis to molecular epidemiology
Maslow, J. N. (1993) · Medical Entomology and Zoology · Cited by 382
Research works printed but not linked: 7
- 1997, MMWR Morb Mortal Wkly Rep, 46, 624
- 2000, MMWR Morb Mortal Wkly Rep, 48, 1165
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: ASM Press, 1999:264-82.
- 2001, MMWR Morb Mortal Wkly Rep, 50, 1
- 1995, MMWR Morb Mortal Wkly Rep, 44, 1
- 1997, MMWR Morb Mortal Wkly Rep, 46, 626
Cited by
Items 101–200 of 1,000
Dunyach-Remy, C., Ngba Essebe, C., Sotto, A., & Lavigne, J.-P. (2016) · Toxins · doi:10.3390/toxins8070209 · Cited by 168
“aureus have been described [84,85].”
Transferable Vancomycin Resistance in a Community-Associated MRSA Lineage
Rossi, F., Diaz, L., Wollam, A., Panesso, D., Zhou, Y., Rincon, S., Narechania, A., Xing, G., Di Gioia, T. S. R., Doi, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1303359 · Cited by 182
Patel, J. B., Jevitt, L. A., Hageman, J., McDonald, L. C., & Tenover, F. C. (2006) · Clinical Infectious Diseases · doi:10.1086/504084 · Cited by 183
Self-citationMellmann, A., Friedrich, A. W., Rosenkötter, N., Rothgänger, J., Karch, H., Reintjes, R., & Harmsen, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030033 · Cited by 179
“Moreover, since the emergence of strains that are insensitive or have reduced sensitivity to glycopeptides, there is a real danger of infections spreading that have even greater drug resistance [5].”
BackgroundStaphylococcal Biofilms: Challenges and Novel Therapeutic Perspectives
Kranjec, C., Morales Angeles, D., Torrissen Mårli, M., Fernández, L., García, P., Kjos, M., & Diep, D. B. (2021) · Antibiotics · doi:10.3390/antibiotics10020131 · Cited by 168
Appelbaum, P. C. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01402.x · Cited by 175
Falord, M., Mäder, U., Hiron, A., Débarbouillé, M., & Msadek, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021323 · Cited by 170
“aureus highlights the growing threat this bacterium poses to human health and the urgent need for developing novel therapeutic approaches [5,6].”
BackgroundFeng, Y., Chen, C.-J., Su, L.-H., Hu, S., Yu, J., & Chiu, C.-H. (2008) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2007.00086.x · Cited by 169
Rat/MgrA, a Regulator of Autolysis, Is a Regulator of Virulence Genes in Staphylococcus aureus
Ingavale, S., van Wamel, W., Luong, T. T., Lee, C. Y., & Cheung, A. L. (2005) · Infection and Immunity · doi:10.1128/iai.73.3.1423-1431.2005 · Cited by 165
Targeting the Microbiota to Address Diet-Induced Obesity: A Time Dependent Challenge
Clarke, S. F., Murphy, E. F., O’Sullivan, O., Ross, R. P., O’Toole, P. W., Shanahan, F., & Cotter, P. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065790 · Cited by 162
“[25,27,28] The cell wall of Gram-negative bacteria is protected by the presence of an outer membrane that blocks the effects of vancomycin.”
BackgroundInhibition of lysine biosynthesis: an evolving antibiotic strategy
Hutton, C. A., Perugini, M. A., & Gerrard, J. A. (2007) · Molecular BioSystems · doi:10.1039/b705624a · Cited by 163
Maor, Y., Hagin, M., Belausov, N., Keller, N., Ben-David, D., & Rahav, G. (2009) · Journal of Infectious Diseases · doi:10.1086/596629 · Cited by 162
“aureus (VRSA), due to presence of the vanA gene complex, have been described [4, 5].”
BackgroundEnterococcal infections: host response, therapeutic, and prophylactic possibilities
Koch, S., Hufnagel, M., Theilacker, C., & Huebner, J. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.11.027 · Cited by 159
“aureus strain in a patient previously colonized with VRE suggests the possibility of an in vivo exchange of resistance traits [14].”
BackgroundGould, F. K., Brindle, R., Chadwick, P. R., Fraise, A. P., Hill, S., Nathwani, D., Ridgway, G. L., Spry, M. J., Warren, R. E., & on behalf of the MRSA Working Party of the British Society for Antimicrobial Chemotherapy (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp065 · Cited by 155
Heunis, T. D. J., Smith, C., & Dicks, L. M. T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00622-13 · Cited by 162
Azimian, A., Havaei, S. A., Fazeli, H., Naderi, M., Ghazvini, K., Samiee, S. M., Soleimani, M., & Peerayeh, S. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01727-12 · Cited by 166
“The vanA gene is not found in any VISA strain (26, 28); however, in 2002, the first vancomycin-resistant Staphylococcus aureus (VRSA) strain was reported in Michigan (8), and in the same year, a second VRSA strain was found in Pennsylvania (6).”
BackgroundResultHershberger, E., Donabedian, S., Konstantinou, K., & Zervos, M. J. (2004) · Clinical Infectious Diseases · doi:10.1086/380125 · Cited by 156
The Role of the Novel Fem Protein VanK in Vancomycin Resistance in Streptomyces coelicolor
Hong, H., Hutchings, M. I., Hill, L. M., & Buttner, M. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413801200 · Cited by 167
Okwu, M. U., Olley, M., Akpoka, O. A., & Izevbuwa, O. E. (2019) · AIMS Microbiology · doi:10.3934/microbiol.2019.2.117 · Cited by 185
“aureus (VRSA) with vancomycin MIC value greater than 16 μg/ml [36,41,45].”
BackgroundBroaders, E., Gahan, C. G. M., & Marchesi, J. R. (2013) · Gut Microbes · doi:10.4161/gmic.24627 · Cited by 146
Nishi, H., Komatsuzawa, H., Fujiwara, T., McCallum, N., & Sugai, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4800-4807.2004 · Cited by 147
Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections
Eleftheriadou, I., Tentolouris, N., Argiana, V., Jude, E. B., & Boulton, A. J. M. (2010) · Drugs · doi:10.2165/11538070-000000000-00000 · Cited by 167
Antimicrobial resistance among gram-negative organisms in the intensive care unit
Clark, N. M., PATTERSON, J. E., & Lynch, J. P. (2003) · Current Opinion in Critical Care · doi:10.1097/00075198-200310000-00012 · Cited by 168
Boswihi, S. S., & Udo, E. E. (2018) · Current Medicine Research and Practice · doi:10.1016/j.cmrp.2018.01.001 · Cited by 171
Zhu, W., Clark, N. C., McDougal, L. K., Hageman, J., McDonald, L. C., & Patel, J. B. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00908-07 · Cited by 117
“The first vanA-mediated, vancomycin-resistant Staphylococcus aureus (VRSA) strain was isolated in a Michigan hospital in 2002 (5, 7).”
BackgroundSelf-citationVancomycin‐Resistant Staphylococcus aureus in the Absence of Vancomycin Exposure
Whitener, C. J., Park, S. Y., Browne, F. A., Parent, L. J., Julian, K., Bozdogan, B., Appelbaum, P. C., Chaitram, J., Weigel, L. M., Jernigan, J., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/382357 · Cited by 147
Self-citationThe need for new therapeutic agents: what is in the pipeline?
SHAH, P. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01141.x · Cited by 163
Qamar, M. T. U., Ahmad, S., Fatima, I., Ahmad, F., Shahid, F., Naz, A., Abbasi, S. W., Khan, A., Mirza, M. U., Ashfaq, U. A., et al. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104389 · Cited by 158
Trends in Antimicrobial Resistance in Health Care–Associated Pathogens and Effect on Treatment
McDonald, L. C. (2006) · Clinical Infectious Diseases · doi:10.1086/499404 · Cited by 147
“The organism accounts for ∼10% of all gramnegative isolates identified in Brooklyn, New York [34].”
BackgroundNicolosi, D., Scalia, M., Nicolosi, V. M., & Pignatello, R. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.01.015 · Cited by 145
“This mechanism of action does not readily permit mutation to resistance [17,18].”
BackgroundHong, H., Hutchings, M. I., Neu, J. M., Wright, G. D., Paget, M. S. B., & Buttner, M. J. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04032.x · Cited by 155
Endocarditis and Intravascular Infections
Fowler, V. G., Scheld, W. M., & Bayer, A. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00082-5 · Cited by 153
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates
Streit, J. M., Fritsche, T. R., Sader, H. S., & Jones, R. N. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.004 · Cited by 144
“aureus (VRSA) in the United States (Center for Disease Control, 2002; Chang et al., 2003).”
BackgroundInfluentialMechanisms of resistance to antibiotics
Wright, G. D. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.08.004 · Cited by 183
Blomquist, P. H. (2006) · PubMed Central · Cited by 177
Current and emerging serious Gram-positive infections
Menichetti, F. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01138.x · Cited by 161
“The gene appeared to have been acquired from an enterococcus (see below) [11].”
BackgroundBacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus aureus
Lade, H., & Kim, J.-S. (2021) · Antibiotics · doi:10.3390/antibiotics10040398 · Cited by 134
“VRSA has been shown to emerge through plasmid transfer of the vanA operon from vancomycinresistant Enterococcus faecalis [61,62].”
BackgroundFlannagan, S. E., Chow, J. W., Donabedian, S. M., Brown, W. J., Perri, M. B., Zervos, M. J., Ozawa, Y., & Clewell, D. B. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3954-3959.2003 · Cited by 129
“The first example of a vancomycin-resistant Staphylococcus aureus (VRSA) strain with the VanA phenotype was isolated during the summer of 2002 from a diabetic patient in Michigan (3, 28).”
BackgroundSelf-citationMicrobial Resistance to Antibiotics and Effective Antibiotherapy
Chiş, A. A., Rus, L. L., Morgovan, C., Arseniu, A. M., Frum, A., Vonica-Țincu, A. L., Gligor, F. G., Mureșan, M.-L., & Dobrea, C. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051121 · Cited by 150
Triple threat: how diabetes results in worsened bacterial infections
Darwitz, B. P., Genito, C. J., & Thurlow, L. R. (2024) · Infection and Immunity · doi:10.1128/iai.00509-23 · Cited by 166
The vancomycin resistance VanRS two‐component signal transduction system of Streptomyces coelicolor
Hutchings, M. I., Hong, H., & Buttner, M. J. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04953.x · Cited by 132
Scherl, A., François, P., Charbonnier, Y., Deshusses, J. M., Koessler, T., Huyghe, A., Bento, M., Stahl-Zeng, J., Fischer, A., Masselot, A., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-296 · Cited by 130
“aureus has been shown to rely on the horizontal transfer of vanA gene from Enterococcus faecalis [7,48], the mechanisms involved in glycopeptide-intermediate resistance remain poorly understood and numerous potential mechanisms are currently explored [11,27].”
Backgroundβ-lactams against methicillin-resistant
Guignard, B., Entenza, J. M., & Moreillon, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.002 · Cited by 149
Acquired Inducible Antimicrobial Resistance in Gram-Positive Bacteria
Chancey, S. T., Zähner, D., & Stephens, D. S. (2012) · Future Microbiology · doi:10.2217/fmb.12.63 · Cited by 150
“com 969 future science group with high-level (VanA-type) VRSA in 2002 [70].”
Marquette, A., & Bechinger, B. (2018) · Biomolecules · doi:10.3390/biom8020018 · Cited by 129
“multi-resistant pathogens [11] they bear great promise to lead the way to new classes of antibiotics capable of counteracting the continuously increasing threat by resistant microorganisms; thus the declining number of effective pharmaceutical agents can be complemented.”
BackgroundVancomycin Resistance VanS/VanR Two-Component Systems
Hong, H., Hutchings, M. I., & Buttner, M. J. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78885-2_14 · Cited by 129
Yin, L., Lazzarini, L., Li, F., Stevens, C. M., & Calhoun, J. H. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki109 · Cited by 129
Impact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus
Watanabe, Y., Cui, L., Katayama, Y., Kozue, K., & Hiramatsu, K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02144-10 · Cited by 127
Malhotra‐Kumar, S., Haccuria, K., Michiels, M., Ieven, M. M., Poyart, C., Hryniewicz, W., & Goossens, H. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00326-08 · Cited by 146
“However, asymptomatic carriage in healthy individuals is common (reviewed in reference 28), and a recent report of an in vivo transmission of vancomycin resistance from GRE to MRSA underscores the potential danger of a coexisting reservoir of both pathogens (5).”
BackgroundGrowth and Laboratory Maintenance of Staphylococcus aureus
Missiakas, D. M., & Schneewind, O. (2013) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc09c01s28 · Cited by 156
“However, vancomycin-resistant (VRSA) phenotypes have emerged and these are associated with the acquisition of resistance genes otherwise found in Enterococcus faecalis (Chang et al., 2003; Weigel et al., 2003).”
BackgroundManagement of Urinary Tract Infections From Multidrug-Resistant Organisms
Gupta, K., & Bhadelia, N. (2013) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2013.10.002 · Cited by 123
Patients at Risk of Complications of Staphylococcus aureus Bloodstream Infection
del Río, A., Cervera, C., Moreno, A., Moreillon, P., & Miró, J. M. (2009) · Clinical Infectious Diseases · doi:10.1086/598187 · Cited by 142
“This evidence has caused increasing concerns about the appropriateness of vancomycin for the treatment of both MSSA and MRSA infections [51, 52, 94] and has led to consideration of the use of more-recently introduced antibiotic agents, such as daptomycin, which has demonstrated efficacy comparable to that of the stand…”
BackgroundBechinger, B. (2014) · Journal of Peptide Science · doi:10.1002/psc.2729 · Cited by 128
Wootton, M., MacGowan, A. P., Walsh, T. R., & Howe, R. A. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01508-06 · Cited by 122
“GRSA strains exhibit vancomycin MICs of 32 mg/liter, having acquired vanA from Enterococcus faecalis/Enterococcus faecium (3, 4).”
BackgroundDalbavancin: a novel antimicrobial
Chen, A. Y., Zervos, M., & Vazquez, J. A. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01318.x · Cited by 123
Arias, C. A., Vallejo, M., Reyes, J., Panesso, D., Moreno, J., Castañeda, E., Villegas, M. V., Murray, B. E., & Quinn, J. P. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01886-07 · Cited by 137
Discovery of Medically Significant Lantibiotics
Piper, C., Cotter, P., Ross, R., & Hill, C. (2009) · Current Drug Discovery Technologies · doi:10.2174/157016309787581075 · Cited by 116
“A, were discovered in Michigan [36, 37], Pennsylvania [38] and New York [39] (see [40] for review).”
BackgroundHenderson, D. K. (2006) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.05.228 · Cited by 143
Battle against Vancomycin-Resistant Bacteria: Recent Developments in Chemical Strategies
Dhanda, G., Sarkar, P., Samaddar, S., & Haldar, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01093 · Cited by 121
Ekambaram, S. P., Perumal, S., Balakrishnan, A., Marappan, N., Gajendran, S., & Viswanathan, V. (2016) · Journal of Intercultural Ethnopharmacology · doi:10.5455/jice.20160906035020 · Cited by 117
“Methicillin-resistant Staphylococcus aureus (MRSA) is a nosocomial and community-acquired pathogen that has developed resistance to various antibiotics such as β-lactams, quinolones, aminoglycosides, vancomycin, oxazolidinone, and streptogramin type antibiotics [2-4].”
Large-Scale Identification of Genes Required for Full Virulence of Staphylococcus aureus
Benton, B. M., Zhang, J. P., Bond, S., Pope, C., Christian, T., Lee, L., Winterberg, K. M., Schmid, M. B., & Buysse, J. M. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.24.8478-8489.2004 · Cited by 113
“Treatment of staphylococcal infections has become increasingly problematic due to the emergence of multidrug-resistant strains, a particular threat being the advent of glycopeptideresistant isolates ( 5 , 61).”
BackgroundAppropriate antibiotic use and why it is important: the challenges of bacterial resistance
Lieberman, J. M. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000101851.57263.63 · Cited by 114
“Clinical isolates of MRSA that were intermediate to vancomycin, called vancomycin-intermediate S. aureus (VISA), were first identified in patients in Japan in 199618; as of June 2002, 8 VISA infections had been documented in patients in the US.19 The mechanism of vancomycin resistance among VISA is not the same as it…”
BackgroundInfluentialBurden of Infection in Patients with End-Stage Renal Disease Requiring Long-Term Dialysis
Berman, S., Johnson, E. W., Nakatsu, C., Alkan, M. L., Chen, R., & LeDuc, J. (2004) · Clinical Infectious Diseases · doi:10.1086/424516 · Cited by 114
PNA FISH: an intelligent stain for rapid diagnosis of infectious diseases
Stender, H. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.5.649 · Cited by 113
Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents
Chakraborty, S. P., Sahu, S. K., Mahapatra, S. K., Santra, S., Bal, M., Roy, S., & Pramanik, P. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/10/105103 · Cited by 122
King, A., Phillips, I., & Kaniga, K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh156 · Cited by 114
Chowdhuri, A. R., Das, B., Kumar, A., Tripathy, S., Roy, S., & Sahu, S. K. (2017) · Nanotechnology · doi:10.1088/1361-6528/aa57af · Cited by 114
Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens
Witte, W., Cuny, C., Klare, I., Nübel, U., Strommenger, B., & Werner, G. (2008) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.10.005 · Cited by 133
“…2002, phenotypically vancomycin-resistant MRSA (VRSA) which had acquired the vanA gene cluster had been isolated from 4 independent cases in the US (1 in Michigan (MI-VRSA), 1 in Pennsylvania (PA-MRSA), and 2 in New York (CDC, 2004; Chang et al., 2003; Tenover et al., 2004; Weigel et al., 2003).”
BackgroundActivation of Inhibitors by Sortase Triggers Irreversible Modification of the Active Site
Maresso, A. W., Wu, R., Kern, J. W., Zhang, R., Janik, D., Missiakas, D. M., Duban, M.-E., Joachimiak, A., & Schneewind, O. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701857200 · Cited by 122
Aisenbrey, C., Marquette, A., & Bechinger, B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3588-4_4 · Cited by 119
New antimicrobial agents as therapy for resistant gram-positive cocci
Lentino, J. R., Narita, M., & Yu, V. L. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0389-y · Cited by 121
tcaA Inactivation Increases Glycopeptide Resistance in Staphylococcus aureus
Maki, H., McCallum, N., Bischoff, M., Wada, A., & Berger-Bächi, B. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.1953-1959.2004 · Cited by 109
Wernitz, M. H., Swidsinski, S., Weist, K., Sohr, D., Witte, W., Franke, K.-P., Roloff, D., Rüden, H., & Veit, S. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01152.x · Cited by 123
“aureus has been reported [22].”
Rybak, M. J. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01342.x · Cited by 121
“However, over-reliance on vancomycin has resulted in the recent development of the first cases of resistance [9–12], and therefore its continued clinical value may be expected to become self-limiting.”
BackgroundCameron, D. R., Ward, D. V., Kostoulias, X., Howden, B. P., Moellering, R. C., Eliopoulos, G. M., & Peleg, A. Y. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis252 · Cited by 109
“monly [1, 2] and have been associated with prolonged bacteremia and vancomycin treatment failures [3–5].”
BackgroundSeverin, A. I., Tabei, K., Tenover, F. C., Chung, M., Clarke, N., & Tomasz, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309593200 · Cited by 107
Self-citationVancomycin-resistance Transferability from VanA Enterococci to Staphylococcus aureus
de Niederhäusern, S., Bondi, M., Messi, P., Iseppi, R., Sabia, C., Manicardi, G., & Anacarso, I. (2011) · Current Microbiology · doi:10.1007/s00284-011-9868-6 · Cited by 103
Glycopeptides: Update on an old successful antibiotic class
Pace, J., & Yang, G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.005 · Cited by 122
Vancomycin-intermediate resistance in Staphylococcus aureus
Hiramatsu, K., Kayayama, Y., Matsuo, M., Aiba, Y., Saito, M., Hishinuma, T., & Iwamoto, A. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.04.006 · Cited by 101
“VRSA for strains whose vancomycin resistance is caused by the horizontally acquired vanA gene complex [5], and VISA for strains whose resistance is caused by accumulation of mutations.”
BackgroundDaptomycin in the Treatment of Patients with Infective Endocarditis: Experience from a Registry
Levine, D. P., & Lamp, K. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.011 · Cited by 105
Glycopeptide Resistance in Gram-Positive Cocci: A Review
Sujatha, S., & Praharaj, I. (2012) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2012/781679 · Cited by 120
“aureus, however, emerged only in 2002 and was first reported from the United States of America [51].”
BackgroundInfluentialFischer, A., Yang, S.-J., Bayer, A. S., Vaezzadeh, A. R., Herzig, S., Stenz, L., Girard, M., Sakoulas, G., Scherl, A., Yeaman, M. R., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr195 · Cited by 104
Enterococcal Urinary Tract Infections: A Review of the Pathogenicity, Epidemiology, and Treatment
Codelia-Anjum, A. J., Lerner, L. B., Elterman, D., Zorn, K. C., Bhojani, N., & Chughtai, B. I. (2023) · Antibiotics · doi:10.3390/antibiotics12040778 · Cited by 135
“Additionally, there have been cases of methicillin-resistant Staphylococcus aureus gaining vancomycin resistance from enterococci [29,30].”
Backgroundβ-Lactam and glycopeptide antibiotics: first and last line of defense?
Jovetic, S., Zhu, Y., Marcone, G. L., Marinelli, F., & TRAMPER, J. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.09.004 · Cited by 128
Tedesco, K. L., & Rybak, M. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.1.41.34802 · Cited by 110
Chakraborty, S. P., Sahu, S. K., Pramanik, P., & Roy, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.033 · Cited by 115
Munir, M. U., Ahmed, A., Usman, M., & Salman, S. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s265934 · Cited by 106
Comenge, Y., Quintiliani, R., Li, L., Dubost, L., Brouard, J., Hugonnet, J., & Arthur, M. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.24.7184-7192.2003 · Cited by 109
“faecium in the late 1980s and the dissemination of the same gene cluster in Staphylococcus aureus 15 years later (8).”
BackgroundShibata, H., Kondo, K., Katsuyama, R., Kawazoe, K., Sato, Y., Murakami, K., Takaishi, Y., Arakaki, N., & Higuti, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.549-555.2005 · Cited by 127
“Although vancomycin and teicoplanin are the two glycopeptides presently used in clinics for the treatment of multiresistant infections by gram-positive organisms, vancomycin-resistant S. aureus has arisen in the United States (4, 5, 6, 8).”
BackgroundWu, Q., Sabokroo, N., Wang, Y., Hashemian, M., Karamollahi, S., & Kouhsari, E. (2021) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-021-00967-y · Cited by 106
RetractedBaddour, M., Abuelkheir, M. M., & Fatani, A. J. (2006) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-5-30 · Cited by 119
“In June 2002 the first clinical isolate of vancomycin resistant Staphylococcus aureus (VRSA) was reported from a patient in Michigan[5].”
Sørum, M. E., Johnsen, P. J., Aasnes, B., Rosvoll, T. C. S., Kruse, H., Sundsfjord, A., & Simonsen, G. S. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.1.516-521.2006 · Cited by 99
“Enterococci are considered the most likely source of VanA-type glycopeptide resistance in recently reported vancomycin-resistant Staphylococcus aureus isolates (13, 14, 36).”
BackgroundRecent trends in antibiotic resistance in European ICUs
van Duijn, P. J., Dautzenberg, M. J. D., & Oostdijk, E. A. N. (2011) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32834c9d87 · Cited by 113
Evolving problems with resistant pathogens
Chastre, J. E. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01958.x · Cited by 113
“aureus (VISA)), shown by MICs ranging from 8 to 16 mg ⁄L, have been documented [46–51].”
BackgroundStaphylococcal Vaccines and Immunotherapies
Schaffer, A. C., & Lee, J. C. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.10.005 · Cited by 108
Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1
Furuno, J. P., Perencevich, E. N., Johnson, J. A., Wright, M., McGregor, J. C., Morris, J. G., Strauss, S. M., Roghmann, M., Nemoy, L. L., Standiford, H. C., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1110.050508 · Cited by 98
“As has been suggested by previously reported cases of VRSA, early identification of these patients is recommended to minimize antimicrobial selective pressure and enhance infection control efforts to reduce the potential for patient-to-patient transmission (5,7).”
BackgroundRisk Factors for Postoperative Mediastinitis Due to Methicillin-Resistant Staphylococcus aureus
Ashley, E. S. D., Carroll, D. N., Engemann, J. J., Harris, A. D., Fowler, V. G., Sexton, D. J., & Kaye, K. S. (2004) · Clinical Infectious Diseases · doi:10.1086/420819 · Cited by 105
Rupp, M. E., Holley, H. P., Lutz, J., Dicpinigaitis, P. V., Woods, C. W., Levine, D. P., Veney, N., & Fowler, V. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00570-07 · Cited by 96
“aureus with resistance to multiple antibiotics, including vancomycin (5), linezolid (19), and daptomycin (16), have limited the options for the treatment of infections caused by this serious pathogen.”
BackgroundMaclayton, D. O., Suda, K. J., Coval, K. A., York, C. B., & Garey, K. W. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.003 · Cited by 103
Sianglum, W., Srimanote, P., Wonglumsom, W., Kittiniyom, K., & Voravuthikunchai, S. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016628 · Cited by 103
Metadata
- Authors
- Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., Cardo, D., & Fridkin, S. K.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Michigan Department of Health and Human Services (US)
- Wayne State University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1342-1347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068037991
- Semantic Scholar
- f0afb59f819a65ada63076a36807f63502c4437d
- Cited by
- 1,095
- References
- 18
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 24 · 2023: 28 · 2022: 24 · 2021: 35 · 2020: 29 · 2019: 39 · 2018: 28 · 2017: 29 · 2016: 28 · 2015: 55 · 2014: 54 · 2013: 51 · 2012: 65
- FWCI
- 54.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- vancomycin-resistant Staphylococcus aureus, vanA gene, vancomycin resistance, diabetes mellitus, peripheral vascular disease, foot ulcer, vancomycin-resistant Enterococcus faecalis, antibiotic resistance transfer, catheter-related infection
- MeSH terms
- Adult, Catheterization, Debridement, Female, Renal Dialysis, Humans, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Contact Tracing, Diabetic Foot, Vancomycin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.